230 related articles for article (PubMed ID: 25906109)
21. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
[TBL] [Abstract][Full Text] [Related]
23. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
24. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
[TBL] [Abstract][Full Text] [Related]
25. [Cross-validation of Quantitative Analytical Software Using 18F-florbetapir PET Imaging].
Wagatsuma K; Miwa K; Sakata M; Ishibashi K; Ishii K
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2021; 77(1):32-40. PubMed ID: 33473077
[TBL] [Abstract][Full Text] [Related]
26. The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden.
Prescott JW; Guidon A; Doraiswamy PM; Roy Choudhury K; Liu C; Petrella JR;
Radiology; 2014 Oct; 273(1):175-84. PubMed ID: 24865310
[TBL] [Abstract][Full Text] [Related]
27. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
28. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
30. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.
Gottesman RF; Schneider AL; Zhou Y; Coresh J; Green E; Gupta N; Knopman DS; Mintz A; Rahmim A; Sharrett AR; Wagenknecht LE; Wong DF; Mosley TH
JAMA; 2017 Apr; 317(14):1443-1450. PubMed ID: 28399252
[TBL] [Abstract][Full Text] [Related]
31. Exploration of neuroanatomical characteristics to differentiate prodromal Alzheimer's disease from cognitively unimpaired amyloid-positive individuals.
Kim HH; Kwon MJ; Jo S; Park JE; Kim JW; Kim JH; Kim SE; Kim KW; Han JW
Sci Rep; 2024 May; 14(1):10083. PubMed ID: 38698190
[TBL] [Abstract][Full Text] [Related]
32. Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study.
Ettore E; Bakardjian H; Solé M; Levy Nogueira M; Habert MO; Gabelle A; Dubois B; Robert P; David R
Sleep; 2019 Sep; 42(9):. PubMed ID: 31267124
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study.
Chen Y; Wang J; Cui C; Su Y; Jing D; Wu L; Liang P; Liang Z
Aging (Albany NY); 2021 Feb; 13(5):7228-7246. PubMed ID: 33640881
[TBL] [Abstract][Full Text] [Related]
34. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
[TBL] [Abstract][Full Text] [Related]
35. Hippocampal Amyloid Burden with Downstream Fusiform Gyrus Atrophy Correlate with Face Matching Task Scores in Early Stage Alzheimer's Disease.
Chang YT; Huang CW; Chen NC; Lin KJ; Huang SH; Chang WN; Hsu SW; Hsu CW; Chen HH; Chang CC
Front Aging Neurosci; 2016; 8():145. PubMed ID: 27378917
[TBL] [Abstract][Full Text] [Related]
36. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
37. Differences in gray and white matter
Son HJ; Oh JS; Roh JH; Seo SW; Oh M; Lee SJ; Oh SJ; Kim JS
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):357-366. PubMed ID: 30109402
[TBL] [Abstract][Full Text] [Related]
38. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
39. The Use of Random Forests to Classify Amyloid Brain PET.
Zukotynski K; Gaudet V; Kuo PH; Adamo S; Goubran M; Scott C; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce R; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE
Clin Nucl Med; 2019 Oct; 44(10):784-788. PubMed ID: 31348088
[TBL] [Abstract][Full Text] [Related]
40. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
Dugger BN; Clark CM; Serrano G; Mariner M; Bedell BJ; Coleman RE; Doraiswamy PM; Lu M; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Zehntner SP; Carpenter AP; Joshi AD; Mintun MA; Pontecorvo MJ; Skovronsky DM; Sue LI; Beach TG
J Neuropathol Exp Neurol; 2014 Jan; 73(1):72-80. PubMed ID: 24335535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
